Published in Lancet on July 31, 1993
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med (2010) 8.72
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev (2006) 3.79
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A (1998) 3.22
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Tuberculosis and HIV co-infection. PLoS Pathog (2012) 2.57
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ (2009) 1.91
Tuberculosis in the AIDS era. Clin Microbiol Rev (1995) 1.85
Pulmonary tuberculosis in Harare, Zimbabwe: analysis by spoligotyping. Thorax (1998) 1.64
Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis (2009) 1.58
Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull World Health Organ (1997) 1.50
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS (2010) 1.37
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2008) 1.34
Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ (1998) 1.34
AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. Thorax (1995) 1.26
Impact of HIV infection on tuberculosis. Postgrad Med J (2000) 1.20
Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ (2003) 1.13
Tuberculosis in the UK, 1994: current issues and future trends. Thorax (1994) 1.13
Recent developments in treatment of latent tuberculosis infection. Indian J Med Res (2011) 1.09
Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc (2011) 1.07
Escalating threat from tuberculosis: the third epidemic. Thorax (1995) 1.06
Depressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol (1998) 1.03
Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci U S A (1998) 1.02
HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. AIDS Patient Care STDS (2009) 1.01
Current integration of tuberculosis (TB) and HIV services in South Africa, 2011. PLoS One (2013) 0.97
The Haiti research-based model of international public health collaboration: the GHESKIO Centers. J Acquir Immune Defic Syndr (2014) 0.96
Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis. Genitourin Med (1996) 0.96
Frequency of tuberculous and non-tuberculous mycobacteria in HIV infected patients from Bogota, Colombia. BMC Infect Dis (2001) 0.95
Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials (2006) 0.94
Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev (2001) 0.94
Successes and challenges of HIV treatment programs in Haiti: aftermath of the earthquake. HIV Ther (2010) 0.94
Tuberculosis: 8. The disease in association with HIV infection. CMAJ (1999) 0.92
Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health (2001) 0.91
A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area. Am J Public Health (2001) 0.88
AIDS in Africans living in London. Genitourin Med (1995) 0.88
Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays. BMC Infect Dis (2011) 0.87
Chemoprophylaxis in tuberculosis and HIV infection. BMJ (1995) 0.86
Early and efficient detection of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. PLoS One (2013) 0.85
HIV Testing among Canadian Tuberculosis Cases from 1997 to 1998. Can J Infect Dis Med Microbiol (2006) 0.84
Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States. AIDS Patient Care STDS (2010) 0.84
A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa. Prev Med (2004) 0.84
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis (2014) 0.84
Trends in CD4 Count Testing, Retention in Pre-ART Care, and ART Initiation Rates over the First Decade of Expansion of HIV Services in Haiti. PLoS One (2016) 0.84
Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings. Med Decis Making (2014) 0.83
The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health (2015) 0.83
Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti. J Acquir Immune Defic Syndr (2013) 0.83
Oral infectious diseases: a potential risk factor for HIV virus recrudescence? Oral Dis (2009) 0.83
Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect (2016) 0.82
Comparison of interferon gamma-inducible protein-10 and interferon gamma-based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagn Microbiol Infect Dis (2011) 0.82
Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study. Int J Tuberc Lung Dis (2009) 0.81
Multiple determinants, common vulnerabilities, and creative responses: addressing the AIDS pandemic in diverse populations globally. J Acquir Immune Defic Syndr (2012) 0.81
Latent tuberculosis treatment. CMAJ (2002) 0.80
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One (2015) 0.79
Correlates of Delayed Diagnosis among Human Immunodeficiency Virus-Infected Pulmonary Tuberculosis Suspects in a Rural HIV Clinic, South Africa. Tuberc Res Treat (2012) 0.79
Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One (2014) 0.79
Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr (2014) 0.79
Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression. Antimicrob Agents Chemother (1995) 0.79
Provision and awareness for isoniazid preventive therapy among PLHIV in Addis Ababa, Ethiopia. BMC Int Health Hum Rights (2012) 0.78
An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health (2011) 0.78
Agreement of decision analyses and subsequent clinical studies in infectious diseases. Am J Med (2007) 0.77
Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen. Int J Tuberc Lung Dis (2012) 0.77
Re-examining treatment of latent tuberculosis infection. Can J Infect Dis (2001) 0.77
Tuberculosis and HIV infection. Lancet (1993) 0.77
Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infect Dis (2016) 0.76
Current management options for latent tuberculosis: a review. Infect Drug Resist (2012) 0.76
Tuberculosis 2000. J R Soc Med (1996) 0.75
Human immunodeficiency virus infection in Haiti. J Natl Med Assoc (1999) 0.75
Tuberculosis and slim disease in Africa. BMJ (1994) 0.75
Liver Function Profile Anomalies in HIV Seropositive Tuberculosis. J Clin Diagn Res (2013) 0.75
Tuberculosis and HIV infection. Lancet (1993) 0.75
Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus. West J Med (1996) 0.75
HIV and AIDS in Africa. 1. Assisting those in the early stages of HIV infection. Am J Public Health (1994) 0.75
Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. BMC Public Health (2017) 0.75
Urban epidemic of severe leptospirosis in Brazil. Salvador Leptospirosis Study Group. Lancet (1999) 7.90
A venue-based method for sampling hard-to-reach populations. Public Health Rep (2001) 6.43
No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr (2001) 6.23
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst (2000) 4.51
The separation, long-term cultivation, and maturation of the human monocyte. J Exp Med (1977) 4.46
Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med (1996) 3.74
Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. N Engl J Med (1983) 3.61
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Double-repetitive-element PCR method for subtyping Mycobacterium tuberculosis clinical isolates. J Clin Microbiol (1995) 3.28
Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products. J Exp Med (1975) 3.17
An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med (1986) 3.12
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun (1981) 2.88
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet (2000) 2.77
Extended treatment of severe coronary artery disease: a total surgical approach. Ann Surg (1969) 2.39
The role of betamethasone in the treatment of acute exudative pharyngitis. Acad Emerg Med (1998) 2.29
A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis (1986) 2.24
Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol (1985) 2.24
Confidence intervals for differences in correlated binary proportions. Stat Med (1997) 2.18
Serious infections caused by diphtheroids. Ann N Y Acad Sci (1970) 2.15
Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09
Therapeutic angiogenesis in patients with advanced coronary artery disease: hype or hope? J Invasive Cardiol (1999) 2.03
Carotid artery stenosis. Association with surgery for coronary artery disease. Arch Surg (1972) 2.01
HIV infection in Haiti: natural history and disease progression. AIDS (2000) 1.97
Women, myocardial infarction, and dementia in the very old. Neurology (1990) 1.94
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Regression toward the mean in 2 x 2 crossover designs with baseline measurements. Stat Med (1992) 1.93
Penicillin-sensitive streptococcal endocarditis. In-vitro and clinical observations on penicillin-streptomycin therapy. Ann Intern Med (1974) 1.92
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
An aggressive surgical approach to coronary disease. J Thorac Cardiovasc Surg (1970) 1.90
Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. AIDS (2001) 1.90
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. Ann Intern Med (1994) 1.85
Cryptosporidium and Isospora belli infections. J Infect Dis (1988) 1.85
Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic. JAMA (1969) 1.80
Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes. J Immunol (1998) 1.76
Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol (1989) 1.66
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med (1989) 1.64
Adequacy of fellowship training: results of a survey of recently graduated fellows. Clin Infect Dis (2001) 1.63
A rapid manual method for CD4+ T-cell quantitation for use in developing countries. AIDS (1993) 1.63
Heterosexual transmission of HIV in Haiti. Ann Intern Med (1996) 1.62
Surgical treatment of syringomyelia based on magnetic resonance imaging criteria. Neurosurgery (1992) 1.60
Gentamicin levels in the human biliary tract. J Infect Dis (1973) 1.58
Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med (1986) 1.56
Potable water as a source of Legionnaires' disease. JAMA (1985) 1.56
Prosthetic valve endocarditis. J Thorac Cardiovasc Surg (1980) 1.56
A prospective study of HIV-seropositive asymptomatic women of childbearing age in a developing country. J Acquir Immune Defic Syndr (1993) 1.55
Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol (2001) 1.54
Sustained bacteremia in patients with prosthetic cardiac valves. N Engl J Med (1972) 1.54
Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Ann Surg Oncol (2002) 1.51
Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest (1989) 1.51
Industrial applications of nanoparticles. Chem Soc Rev (2015) 1.49
Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis (1996) 1.48
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Transmission of multidrug-resistant tuberculosis in a large urban setting. Am J Respir Crit Care Med (1995) 1.41
Serum lipid changes in medical students. J Am Diet Assoc (1978) 1.40
The expanding spectrum of IgA pemphigus: a case report and review of the literature. Br J Dermatol (2014) 1.40
Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg (1996) 1.39
Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis (1987) 1.32
Additive statistical effects of cadmium and lead on heart-related disease in a North Carolina autopsy series. Arch Environ Health (1982) 1.32
Diphtheroid endocarditis after insertion of a prosthetic heart valve. Report of two cases. JAMA (1968) 1.30
Vancomycin therapy of bacterial endocarditis. Am J Med (1978) 1.30
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis (1996) 1.29
The physiologic parameters of ventricular function as affected by direct coronary surgery. J Thorac Cardiovasc Surg (1970) 1.29
Altitude and arteriosclerotic heart disease mortality in white residents of 99 of the 100 largest cities in the United States. J Chronic Dis (1979) 1.27
IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J Immunol (1993) 1.27
Bending stiffness of unilateral and bilateral fixator frames. Clin Orthop Relat Res (1983) 1.24
Complications following surgery for duodenal ulcer in obese patients. Arch Surg (1972) 1.23
Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst (1980) 1.23
The epidemiology of colorectal polyps: prevalence in New Orleans and international comparisons. Cancer (1977) 1.23
Fatty acid composition of human adipose tissue from two anatomical sites in a biracial community. Am J Clin Nutr (1979) 1.18
Cyclospora: conquest of an emerging pathogen. Lancet (1995) 1.18
In vitro antimicrobial activity and human pharmacology of cephaloglycin. Appl Microbiol (1968) 1.18
History of hydrocephalus and its treatments. Neurosurg Focus (2001) 1.17
Direct coronary surgery utilizing multiple-vein bypass grafts. Ann Thorac Surg (1970) 1.17
Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med (2000) 1.16
Asymptomatic Chlamydia trachomatis infections among sexually active men. J Infect Dis (1986) 1.13
Late results of saphenous vein bypass grafting for myocardial revascularization. Ann Thorac Surg (1972) 1.13
Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. J Cell Sci (1999) 1.12
Employment patterns in males before and after myocardial revascularization surgery. A study of 2229 consecutive male patients followed for as long as 10 years. Circulation (1982) 1.10
Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10
Serum creatine phosphokinase in leptospirosis. JAMA (1975) 1.10
Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci U S A (1996) 1.10
The "bad" left ventricle. Results of coronary surgery and effect on late survival. J Thorac Cardiovasc Surg (1976) 1.09
Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol (1991) 1.09
Determinants of blood flow in aortic-coronary saphenous vein bypass grafts. Arch Surg (1970) 1.09
Observation of time-reversal violation in the B0 meson system. Phys Rev Lett (2012) 1.09
Relationship between respiratory cancer and wetlands residency in Louisiana. Arch Environ Health (1978) 1.07
Precise measurement of the e+e- --> pi+pi-(gamma) cross section with the initial state radiation method at BABAR. Phys Rev Lett (2009) 1.07
Recurrent urban histoplasmosis, Indianapolis, Indiana, 1980-1981. Am J Epidemiol (1983) 1.07
Simultaneous valve replacement and aorta-to-coronary saphenous vein bypass. Ann Thorac Surg (1971) 1.06
Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.05
Sources of HIV information among injecting drug users: association with gender, ethnicity, and risk behaviour. AIDS Community Demonstration Projects. AIDS Care (1996) 1.05
Measurement of |V(cb)| and the form-factor slope in B --> Dl- nu(l) decays in events tagged by a fully reconstructed B meson. Phys Rev Lett (2010) 1.05